A cost-benefit analysis of preimplantation genetic diagnosis for carrier couples of cystic fibrosis  

Oleh:

Davis, Lynn B. ; Champion, Sara J. ; Fair, Steve O.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 93 no. 06 (Apr. 2010), page 1793-1804.
Topik: Preimplantation genetic diagnosis; preimplantation genetic screening; cost-benefit analysis; cystic fibrosis; carrier

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2010.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective To perform a cost-benefit analysis of preimplantation genetic diagnosis (PGD) for carrier couples of cystic fibrosis (CF) compared with the alternative of natural conception (NC) followed by prenatal testing and termination of affected pregnancies. Design Cost-benefit analysis using a decision analytic model. Setting Outpatient reproductive health practices. Patient(s) A simulated cohort of 1,000 female patients. Intervention(s) We calculated the net benefit of giving birth to a child as the present value of lifetime earnings minus lifetime medical costs. Main Outcome Measure(s) Net benefits in dollars. Result(s) When used for women younger than 35 years of age, the net benefit of PGD over NC was $182,000 ($715,000 vs. $532,000, respectively). For women aged 35–40 years, the net benefit of PGD over NC was $114,000 ($634,000 vs. $520,000, respectively). For women older than 40 years, however, the net benefit of PGD over NC was -$148,000 ($302,000 vs. $450,000, respectively). Conclusion(s) Preimplantation genetic diagnosis provides net economic benefits when used by carrier couples of CF. Although there is an upper limit of maternal age at which economic benefit can be demonstrated, carrier couples of CF should be offered PGD for prevention of an affected child.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali